Vontobel Holding’s Compass Therapeutics CMPX Stock Holding History

Vontobel Holding’s Portfolio CMPX Stock Details CMPX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-29,882	Closed	-$56.8K	–	1267
2025 Q1	$56.8K	Buy	+29,882	New	+$79.5K	﹤0.01%	1059

Other funds holding CMPX

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Vontobel Holding's CMPX Position: Q2 2025 in Review

Vontobel Holding sold out of Compass Therapeutics (CMPX) in Q2 2025, closing a stake of 29,882 shares — an estimated $56.8K sold.

Vontobel Holding first reported a position in CMPX in Q1 2025 and held it in 1 quarter. The position peaked at $56.8K in Q1 2025. 103 funds tracked by Wall St. Rank hold CMPX as of Q2 2025.

Vontobel Holding reported no remaining Compass Therapeutics position as of Q2 2025 after selling out during the quarter.
Vontobel Holding sold 29,882 Compass Therapeutics shares in Q2 2025, an estimated $56.8K.
Vontobel Holding first reported a position in Compass Therapeutics in Q1 2025 and held it in 1 quarter.
Vontobel Holding's Compass Therapeutics position peaked at $56.8K in Q1 2025.
103 funds tracked by Wall St. Rank held Compass Therapeutics as of Q2 2025.

Based on Vontobel Holding's 13F filing for Q2 2025, filed 23 Jul 2025.